http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20060123452-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
filingDate 2004-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c732299fe74bce5ce297454ca74d3c8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa246da9fa54edb60ac9b3cf137bbf8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f119f5020589c385e93e970c8a2d7f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507b226db040144eaf921d8e948c5576
publicationDate 2006-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20060123452-A
titleOfInvention Its use as a modulator of naphthyridine derivatives and muscarinic receptors
abstract A compound of formula I that modulates muscarinic receptors and is useful for the treatment of muscarinic receptor mediated diseases.n n n <Formula I>n n n n n n n n Wherein ring A is aryl or heteroaryl; One of V, W, Y or Z is nitrogen and the other of V, W, Y and Z is -C (R 5 )-.
priorityDate 2003-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420637524
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420815330
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420637508
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421525387
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20753057
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59831523
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420815336
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421339846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421020896
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11161159
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421339856
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59831524
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467428402
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID76622
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7476
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419529934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10778956
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59831528
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11414056
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11379035
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421784073
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422283712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID59831529
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420637495
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11459510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466575918

Total number of triples: 57.